section name header

Interacting Drugs

OBJECT DRUGS

PRECIPITANT DRUGS

Enzyme Inhibitors:


Comment:

Eplerenone is metabolized primarily by CYP3A4, and inhibitors of CYP3A4 may produce marked increases the serum levels of eplerenone. This may increase the risk of eplerenone toxicity, and the manufacturer states that eplerenone is contraindicated with potent CYP3A4 inhibitors. Aprepitant is a moderate inhibitor of CYP3A4, but is also likely to increase eplerenone concentrations.


Class 2: Use Only if Benefit Felt to Outweigh Risk